Docetaxel Combined with Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer

Clinical Lung Cancer

Volumn 17, Issue 3, 2016, Pages 169-176

  Gerber, David E ^a,h   Spigel, David R ^b   Giorgadze, David ^c   Shtivelband, Mikhail ^d   Ponomarova, Olga V ^e   Shan, Joseph S ^f   Menander, Kerstin B ^f   Belani, Chandra P ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PLLC   (United States)

^c Medulla Chemotherapy and Immunotherapy Clinic   (Georgia)

^d Ironwood Cancer and Research Center   (United States)

^e Department of Neurology No 1   (Ukraine)

^f Peregrine Pharmaceuticals Inc   (United States)

^g PENN STATE CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Macrophages; Monoclonal antibody; Phosphatidylserine; Tumor microenvironment

Indexed keywords

BAVITUXIMAB; DOCETAXEL; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HUMAN; HYPOTENSION; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; VOMITING; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; IMMUNOTHERAPY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84971617618     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.02.003     Document Type: Article

References (37)

1. J. Brahmer, K.L. Reckamp, P. Baas, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 2015 123 135
2. H. Borghaei, L. Paz-Ares, L. Horn, and et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 2015 1627 1639
3. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, Published online December 18, 2015; http://dx.doi.org/10.1016/S0140-6736(15)01281-7.
4. U.S. Gaipl, T.D. Beyer, I. Baumann, and et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal - implications for antiphospholipid syndrome and systemic lupus erythematosus Immunobiology 207 2003 73 81
5. R.E. Voll, M. Herrmann, E.A. Roth, C. Stach, J.R. Kalden, and I. Girkontaite Immunosuppressive effects of apoptotic cells Nature 390 1997 350 351
6. P.R. Hoffmann, A.M. deCathelineau, C.A. Ogden, and et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells J Cell Biol 155 2001 649 659
7. V.A. Fadok, D.L. Bratton, A. Konowal, P.W. Freed, J.Y. Westcott, and P.M. Henson Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF J Clin Invest 101 1998 890 898
8. J. He, Y. Yin, T.A. Luster, L. Watkins, and P.E. Thorpe Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma Clin Cancer Res 15 2009 6871 6880
9. S. Ran, J. He, X. Huang, M. Soares, D. Scothorn, and P.E. Thorpe Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice Clin Cancer Res 11 2005 1551 1562
10. D.L. Daleke Regulation of transbilayer plasma membrane phospholipid asymmetry J Lipid Res 44 2003 233 242
11. M. Jennewein, M.A. Lewis, D. Zhao, and et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine Clin Cancer Res 14 2008 1377 1385
12. A.W. Beck, T.A. Luster, A.F. Miller, and et al. Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice Int J Cancer 118 2006 2639 2643
13. S. Riedl, B. Rinner, M. Asslaber, and et al. In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy Biochim Biophys Acta 1808 2011 2638 2645
14. X. Huang, M. Bennett, and P.E. Thorpe A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice Cancer Res 65 2005 4408 4416
15. J. He, T.A. Luster, and P.E. Thorpe Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids Clin Cancer Res 13 2007 5211 5218
16. J. Gong, R. Archer, M. Brown, and et al. Measuring response to therapy by near-infrared imaging of tumors using a phosphatidylserine-targeting antibody fragment Mol Imaging 12 2013 244 256
17. D.E. Gerber, G. Hao, L. Watkins, and et al. Tumor-specific targeting by bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties in lung cancer xenografts Am J Nucl Med Mol Imaging 5 2015 493 503
18. D.E. Gerber, A.T. Stopeck, L. Wong, and et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors Clin Cancer Res 17 2011 6888 6896
19. R. Digumarti, P.P. Bapsy, A.V. Suresh, and et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer Lung Cancer 86 2014 231 236
20. P. Chalasani, M. Marron, D. Roe, and et al. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer Cancer Med 4 2015 1051 1059
21. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
22. Y. Yin, X. Huang, K.D. Lynn, and P.E. Thorpe Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation Cancer Immunol Res 1 2013 256 268
23. S. Ran, and P.E. Thorpe Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy Int J Radiat Oncol Biol Phys 54 2002 1479 1484
24. F.A. Shepherd, J. Dancey, R. Ramlau, and et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
25. N. Hanna, F.A. Shepherd, F.V. Fossella, and et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
26. E.B. Garon, T.E. Ciuleanu, O. Arrieta, and et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial Lancet 384 2014 665 673
27. M. Reck, R. Kaiser, A. Mellemgaard, and et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Lancet Oncol 15 2014 143 155
28. A. Sandler, R. Gray, M.C. Perry, and et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
29. M. Reck, J. von Pawel, P. Zatloukal, and et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) Ann Oncol 21 2010 1804 1809
30. G.H. Sack Jr., J. Levin, and W.R. Bell Trousseau syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features Medicine (Baltimore) 56 1977 1 37
31. J.W. Blom, C.J. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 2005 715 722
32. A.A. Khorana Cancer and thrombosis: implications of published guidelines for clinical practice Ann Oncol 20 2009 1619 1630
33. A.A. Khorana Cancer-associated thrombosis: updates and controversies Hematology Am Soc Hematol Educ Program 2012 2012 626 630
34. T.J. Lynch, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
35. M. Reck, I. Bondarenko, A. Luft, and et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
36. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
37. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465